[Genetic Counselor]

Rett syndrome is a genetic disorder, but in most cases, it is not inherited from either parent. More than 99% of affected individuals are the only known person with the condition in their family. This usually happens because a new genetic change, known as a de novo variant, occurs during the formation of an egg or sperm or during early embryonic development. NCBI

What does de novo mean?
A de novo variant is a genetic change that occurs for the first time in an individual rather than being passed down through a family.
For example, a child may be born to two healthy parents with no family history of neurological disorders. During the formation of the reproductive cells or shortly after fertilization, a pathogenic variant may arise in the MECP2 gene. The child may subsequently develop Rett syndrome.
In such cases, the parents may not carry the variant in their blood or other routinely tested tissues.
Therefore, having no family history does not exclude a genetic disorder. Many genetic conditions arise spontaneously.

Can Rett syndrome be inherited from the mother?
Yes, although this is uncommon.
Rett syndrome associated with MECP2 follows an X-linked dominant inheritance pattern. The MECP2 gene is located on the X chromosome, one of the two sex chromosomes.
Typically, females have two X chromosomes, whereas males have one X and one Y chromosome.
A female who carries a pathogenic MECP2 variant may have Rett syndrome or may have mild or no obvious symptoms. The severity can vary because of a biological process called X-chromosome inactivation.
During early development, one of the two X chromosomes is largely inactivated in each cell of a female. If the X chromosome carrying the pathogenic variant is predominantly inactivated in relevant tissues, the mother may have few or no clinical symptoms.
If a mother is confirmed to carry a heterozygous pathogenic MECP2 variant, each pregnancy has a 50% chance of inheriting that variant, regardless of the child’s sex. However, the clinical outcome can differ between male and female offspring.

What is germline mosaicism?
Germline mosaicism is another important concept in genetic counselling.
It occurs when a genetic variant is present in some of a parent’s reproductive cells, such as eggs or sperm, but is absent from the parent’s blood cells or other tested tissues.
For example, both parents may have negative blood tests for the child’s MECP2 variant. However, one parent may have the variant in a proportion of their reproductive cells.
This explains why a condition can occasionally recur in a family even when neither parent appears to carry the variant.
Consequently, a negative parental blood test does not completely eliminate the possibility of recurrence.

What is the recurrence risk for future pregnancies?
When the variant is confirmed to be de novo and is not detected in either parent’s blood, the recurrence risk is generally low, often estimated at less than 1%. However, it is not zero because germline mosaicism may be present.
If a mother carries a heterozygous pathogenic variant, the risk of transmitting it is 50% in each pregnancy.
Genetic counselling can help families understand their individual risk. Depending on the circumstances, options may include targeted parental testing, prenatal diagnosis through chorionic villus sampling (CVS) or amniocentesis, and preimplantation genetic testing.

[Genetic Counselor]

Rett syndrome is a rare genetic neurodevelopmental disorder that primarily affects brain development and function. It is characterized by a period of apparently typical early development followed by a loss of previously acquired skills, including speech, purposeful hand movements, and motor abilities. It occurs predominantly in females and is most commonly associated with changes in the MECP2 gene located on the X chromosome.

Role of the MECP2 gene
The MECP2 gene provides instructions for producing methyl-CpG-binding protein 2 (MeCP2). This protein plays an important role in regulating gene expression, particularly in the brain. It helps control the activity of numerous other genes involved in the development, maintenance, and functioning of nerve cells.
Brain cells, called neurons, communicate with one another through specialized connections known as synapses. MeCP2 contributes to the regulation of neuronal maturation, synaptic function, and the maintenance of healthy neural networks.
When the MECP2 gene contains a disease-causing variant, the protein may be absent, produced in insufficient amounts, or unable to function properly. This disrupts the regulation of genes necessary for normal brain function.
As a result, the development and functioning of neural networks may be affected, leading to the characteristic features of Rett syndrome.

How do genetic changes cause the condition?
Most cases of classic Rett syndrome are associated with pathogenic variants in the MECP2 gene. These variants may include:
– Missense variants: A change in one DNA nucleotide alters an amino acid in the protein.
– Nonsense variants: A DNA change introduces a premature stop signal, potentially resulting in a shortened protein.
– Frameshift variants: Insertions or deletions alter the reading frame of the gene.
– Splice-site variants: Changes affect the processing of RNA, potentially altering the final protein.
– Deletions: Part or, occasionally, all of the gene may be missing.
Different variants can affect protein function in different ways. However, the relationship between a particular variant and the severity of symptoms is not always straightforward.

Is Rett syndrome always caused by an MECP2 variant?
No. Although MECP2 is the principal gene associated with classic Rett syndrome, not every person with Rett-like features has an identifiable pathogenic variant in this gene.
Some individuals have Rett-like disorders caused by changes in other genes, including CDKL5 and FOXG1. These conditions have distinct clinical and genetic characteristics and are often classified separately from classic Rett syndrome.
Genetic testing helps distinguish these conditions and supports an accurate diagnosis.

Why does Rett syndrome usually occur spontaneously?
In most affected individuals, the pathogenic variant arises de novo, meaning it occurs for the first time in the affected child rather than being inherited from a parent.
A de novo variant may arise during the formation of an egg or sperm or very early after fertilization. Consequently, parents can have no symptoms and no known family history of the condition.
Rarely, a variant may be inherited from a mother who carries it, including a mother who has few or no obvious symptoms.

Can Rett syndrome be prevented?
There is currently no established method to prevent the spontaneous genetic changes that cause Rett syndrome. However, genetic counselling can help families understand the diagnosis, inheritance pattern, recurrence risk, and reproductive options.

[Genetic Counselor]

Rett syndrome and autism spectrum disorder (ASD) are both neurodevelopmental conditions that can affect communication, behaviour, and social interaction. Some children with Rett syndrome initially receive an autism diagnosis because the conditions share certain clinical features.
However, Rett syndrome is a distinct genetic disorder characterized by a particular pattern of developmental regression, loss of purposeful hand movements, and other neurological features. Autism spectrum disorder is a broader diagnosis based on persistent differences in social communication and interaction, together with restricted or repetitive behaviours and interests. NCBI

1. Genetic cause
Rett syndrome: Classic Rett syndrome is most commonly associated with pathogenic variants in the MECP2 gene on the X chromosome. These variants disrupt normal brain function and development.
Autism spectrum disorder: Autism is genetically complex. It can arise through the combined effects of many genetic variants, environmental influences, and, in some individuals, identifiable genetic conditions. There is no single gene responsible for all cases of autism.
Genetic testing may be recommended for autistic individuals when clinical features or family history suggest an underlying genetic condition.

2. Developmental regression
Rett syndrome: A characteristic feature is the loss of previously acquired skills after a period of early development. The child may lose purposeful hand use, spoken language, and some motor abilities.
Autism: Some autistic children also experience developmental regression, particularly involving language or social skills. However, regression is not required for an autism diagnosis, and its pattern varies.
The presence of regression alone cannot distinguish Rett syndrome from autism. The overall developmental history and accompanying clinical features are important.

3. Hand movements
Rett syndrome: One of the most distinctive features is the partial or complete loss of purposeful hand skills, accompanied by repetitive, stereotyped movements. These may include hand wringing, washing-like movements, clapping, or tapping.
Autism: Repetitive movements can also occur in autism. Examples include hand flapping, rocking, spinning objects, or repeating particular actions.
The key difference is that in classic Rett syndrome, repetitive hand movements typically emerge as purposeful hand skills are lost.

4. Speech and communication
Rett syndrome: Children may lose previously acquired spoken language. Some individuals retain limited speech, while others rely heavily on eye gaze, gestures, communication boards, or assistive communication devices.
Autism: Communication abilities vary widely. Some autistic individuals have fluent speech, while others have limited or no spoken language. Difficulties may involve both verbal and nonverbal communication.
Therefore, the absence of speech alone cannot establish a diagnosis of Rett syndrome.

5. Motor function and breathing
Rett syndrome: Motor difficulties are common and may include problems with walking, balance, coordination, and purposeful hand use. Abnormal breathing patterns, such as breath-holding or hyperventilation while awake, can also occur.
Autism: Motor coordination difficulties may occur, but they are not defining features of autism. Breathing irregularities of the characteristic type seen in Rett syndrome are not a core diagnostic feature of autism.
These differences can help clinicians determine whether further neurological or genetic evaluation is necessary.

6. How are the conditions diagnosed?
Rett syndrome is diagnosed through clinical assessment using established diagnostic criteria, supported by MECP2 genetic testing when indicated.
Autism is diagnosed through a comprehensive developmental assessment that examines social communication, interaction, behaviour, and developmental history. There is no single genetic test that can diagnose autism in every individual.

[Genetic Counselor]

Rett syndrome is usually recognized during early childhood, although the exact age of diagnosis varies between individuals. Many affected children appear to develop relatively typically during the first 6–18 months of life. After this period, developmental progress may slow, followed by the loss of previously acquired skills.
The characteristic regression often occurs between 1 and 4 years of age, although the timing and severity vary. Some children may show signs earlier or later, and genetic testing can help establish the diagnosis before all the typical clinical features have developed. NCBI

Stage 1: Early development (birth to approximately 6–18 months)
During the first few months of life, a baby with classic Rett syndrome may appear to develop normally.

The child may acquire early skills such as:
– Making eye contact.
– Smiling and interacting with caregivers.
– Reaching for objects.
– Sitting with support.
– Babbling and making sounds.

However, some children may have subtle developmental differences that become apparent only in retrospect.
For example, parents may notice reduced interest in toys, slower acquisition of motor skills, or less frequent use of their hands.
These early signs are not specific to Rett syndrome and may occur in several other developmental conditions.

Stage 2: Developmental stagnation and regression (approximately 1–4 years)
This is often the most recognizable period in classic Rett syndrome.
Developmental regression means losing skills that a child had already acquired.
Possible changes include:
– Loss of purposeful hand movements: The child may no longer reach for or manipulate objects as effectively.
– Loss of spoken language: Previously acquired words may disappear, and communication may become increasingly limited.
– Repetitive hand movements: Hand wringing, washing-like movements, clapping, or tapping may replace purposeful hand use.
– Motor difficulties: Sitting, standing, walking, and maintaining balance may become difficult.
– Social and behavioural changes: The child may show changes in interaction, attention, or emotional responses.
– Breathing irregularities: Episodes of breath-holding or hyperventilation may develop, particularly while awake.
Some of these features can resemble autism spectrum disorder, cerebral palsy, or other neurological conditions. This can make early diagnosis challenging.

Stage 3: Stabilization or partial recovery
Following the regression period, many children enter a stage in which the rapid loss of skills slows or stops.
Some individuals show improvements in eye contact, attention, communication, or social interaction. However, difficulties with purposeful hand use, speech, and mobility may persist.
This stage does not mean that the underlying genetic condition has disappeared. Rather, the clinical course may become more stable.

Stage 4: Later motor complications
As individuals grow older, motor difficulties may become more prominent.
Possible complications include:
– Scoliosis, or abnormal curvature of the spine.
– Muscle stiffness or abnormal muscle tone.
– Reduced mobility.
– Joint contractures.
– Feeding difficulties and poor weight gain.
– Constipation and other gastrointestinal problems.
Not every individual develops all these complications. Their severity depends on the person’s clinical course and overall health.

How is Rett syndrome diagnosed?
Diagnosis involves a combination of clinical assessment and genetic testing.
Clinical evaluation includes reviewing developmental milestones, identifying any loss of previously acquired skills, examining hand movements, and assessing walking, communication, and other neurological features.
Genetic testing can identify a pathogenic variant in the MECP2 gene. Testing may include gene sequencing and deletion/duplication analysis. If the findings suggest another genetic condition, a broader genetic panel or genomic test may be appropriate.
A negative MECP2 result does not automatically exclude every Rett-like disorder. The clinical findings and other possible genetic causes must also be considered

[Genetic Counselor]

Yes. Although Rett syndrome predominantly affects females, boys can also develop conditions associated with pathogenic variants in the MECP2 gene. The clinical presentation in males can differ considerably from that in females.
Classic Rett syndrome is much more commonly recognized in girls. In boys, an MECP2 variant may cause a severe neurological condition beginning in the neonatal period, intellectual disability, or another MECP2-related disorder. Rare males have also been reported with a clinical presentation resembling classic Rett syndrome. MedlinePlus

Why is Rett syndrome usually more severe in boys?
The explanation involves the sex chromosomes and the function of the MECP2 gene.
Most females have two X chromosomes, while most males have one X chromosome and one Y chromosome.
In females with Rett syndrome, one copy of the MECP2 gene may contain a pathogenic variant, while the other copy may function normally. X-chromosome inactivation determines which X chromosome is predominantly active in individual cells.
This creates a mixture of cells expressing the altered or unaffected copy of the gene. The distribution of these cells contributes to the variability in clinical severity.
In males with a typical 46,XY chromosome pattern, there is only one copy of the MECP2 gene. A severe pathogenic variant can therefore affect gene function across many cells without a second copy on another X chromosome.
This may lead to severe neurological dysfunction, sometimes beginning shortly after birth.

What conditions can occur in boys with MECP2 variants?

1. MECP2-related severe neonatal encephalopathy
This is a severe neurological condition that can occur in males with certain pathogenic MECP2 variants.
Clinical features may include:
– Severe developmental impairment beginning early in life.
– Abnormal muscle tone.
– Seizures.
– Involuntary movements.
– Breathing abnormalities.
– Difficulties with feeding and other neurological functions.
The condition can be life-threatening, and many severely affected boys die in infancy or early childhood.

2. Rett-like clinical presentations
Rare males may develop features resembling Rett syndrome, including intellectual disability, loss of skills, seizures, and movement difficulties.
These presentations may occur in individuals with an additional X chromosome, such as those with a 47,XXY karyotype, or in individuals with mosaicism.

3. Other MECP2-related disorders
Not every male with an MECP2 variant has Rett syndrome or severe neonatal encephalopathy. Other associated conditions include intellectual disability and PPM-X syndrome, which is characterized by pyramidal signs, parkinsonism, and macroorchidism.
It is also important to distinguish MECP2-related disorders from MECP2 duplication syndrome. Duplication syndrome results from an extra copy of the gene and is a separate condition, not the same as Rett syndrome.

What is mosaicism?
Mosaicism occurs when an individual has two or more genetically different cell populations that originated from the same fertilized egg.
For example, an MECP2 variant may arise after fertilization, meaning that only a proportion of the body’s cells carry the variant. This can influence the clinical presentation.
The severity depends on several factors, including the specific variant, the proportion of affected cells, and their distribution in different tissues.

How is the diagnosis confirmed in boys?
Clinical assessment and genetic testing are important. Depending on the presentation, testing may include MECP2 sequencing and deletion/duplication analysis. Chromosome analysis may also be considered when a sex-chromosome abnormality is suspected.
A genetic counsellor can explain the findings, inheritance implications, and testing options for family members.

[Genetic Counselor]

Early diagnosis of mucopolysaccharidosis (MPS) is important because it allows treatment and supportive care to begin before significant, potentially irreversible organ damage occurs. MPS is a group of inherited metabolic disorders in which a deficiency of specific enzymes causes glycosaminoglycans (GAGs) to accumulate in cells and tissues.

1. Early Treatment Can Improve Outcomes
Some treatments, including enzyme replacement therapy (ERT) and haematopoietic stem cell transplantation (HSCT) for selected patients, can improve outcomes. Treatment is often more beneficial when started early, depending on the MPS type.

2. Preventing or Managing Organ Complications
Early diagnosis helps doctors monitor and manage complications affecting the heart, lungs, liver, bones, joints, hearing, and vision. Although not all complications can be prevented, timely intervention can improve health and quality of life.

3. Protecting Development and Cognitive Function
Some MPS types, particularly severe MPS I and MPS II, can cause progressive neurological involvement. In selected children with severe MPS I, early HSCT may help preserve cognitive function. Early recognition of developmental changes also supports timely intervention.

4. Access to Appropriate Treatment and Specialist Care
A confirmed diagnosis helps healthcare professionals develop an individualised management plan involving clinical geneticists, paediatricians, cardiologists, orthopaedic specialists, and other healthcare professionals as needed.

5. Genetic Counselling and Family Planning
MPS is usually inherited in an autosomal recessive pattern, except MPS II, which is typically X-linked. Genetic counselling can help families understand inheritance, recurrence risks, carrier testing, and reproductive options.

6. Avoiding Diagnostic Delays
Early identification of symptoms such as unexplained hernias, recurrent respiratory infections, skeletal abnormalities, joint stiffness, or developmental delays can prompt appropriate biochemical and genetic investigations.

[Genetic Counselor]

No. A normal urine glycosaminoglycan (GAG) test cannot completely rule out mucopolysaccharidosis (MPS). Although urinary GAG analysis is commonly used as an initial screening investigation, some affected individuals may have normal or borderline results.

This is an important consideration when evaluating children with clinical features suggestive of an inherited metabolic disorder.

Why can a urine test be normal in MPS?
Mucopolysaccharidosis occurs when the body lacks sufficient activity of a specific enzyme required to break down glycosaminoglycans. These substances accumulate in tissues and may also be excreted in urine.

Urinary GAG testing looks for abnormalities in the amount or pattern of these substances. However, the result can be influenced by several factors.
1. Mild or attenuated forms of MPS
Some individuals with milder forms of mucopolysaccharidosis may excrete smaller amounts of GAGs. Their urinary results may fall within the laboratory’s reference range despite having the disorder.

2. Age-related differences
Urinary GAG levels vary with age. Interpretation must therefore take the patient’s age and the laboratory’s reference intervals into account.

3. Limitations of the testing method
Different laboratories use different methods to measure urinary GAGs. Some screening methods measure total GAG concentration, while others identify specific GAG patterns.
A test that measures total GAGs may not detect every affected individual, particularly when the abnormality is subtle.

4. Differences between MPS types
The sensitivity of urinary screening varies between MPS types. Patients with Morquio syndrome (MPS IVA or IVB) and some individuals with attenuated Sanfilippo syndrome (MPS III) may have less pronounced urinary GAG abnormalities.
Therefore, a normal screening result should not automatically end the diagnostic investigation when clinical suspicion remains high.

What should be done if the urine test is normal?
If the clinical features strongly suggest mucopolysaccharidosis, the next step is to consider further investigations rather than relying solely on the screening result.

The evaluation may include:
1. Specific enzyme activity testing
This assesses the activity of the enzyme associated with the suspected MPS type. It is a central investigation for confirming the biochemical diagnosis.

2. Molecular genetic testing
Testing the relevant genes can identify disease-associated variants and help establish the molecular diagnosis. The results should be interpreted alongside enzyme activity and clinical findings.

3. Specialist evaluation
A clinical geneticist or metabolic disease specialist can assess the patient’s symptoms, determine which investigations are appropriate, and consider alternative diagnoses if MPS is not confirmed.

Can genetic testing be performed after a normal urine result?
Yes. When symptoms suggest mucopolysaccharidosis, genetic testing may be appropriate despite a normal urine screening result. However, genetic testing should be selected and interpreted carefully because not every detected variant is disease-causing.
A variant of uncertain significance cannot independently confirm MPS, and a negative genetic result may require further evaluation depending on the test’s scope and the patient’s clinical presentation.

Why does early diagnosis matter?
Delaying diagnosis because of a normal screening result may postpone appropriate treatment and monitoring. Some MPS-specific treatments are most beneficial when started early, before significant complications develop.

[Genetic Counselor]

Currently, there is no universal cure for mucopolysaccharidosis (MPS). However, several treatment options can manage symptoms, reduce certain disease complications, and improve quality of life. For selected MPS types, treatments may also slow disease progression.

Mucopolysaccharidosis is caused by deficiencies in specific enzymes needed to break down glycosaminoglycans (GAGs). These substances accumulate in different tissues and organs, potentially affecting the skeleton, heart, respiratory system, liver, and other parts of the body.
The treatment approach depends on the specific MPS type, disease severity, age at diagnosis, and organs affected.

1. Enzyme replacement therapy (ERT)
Enzyme replacement therapy involves administering a laboratory-produced version of the enzyme that is deficient in a particular MPS type.
ERT is available for several types, including MPS I, II, IVA, VI, and VII, depending on the country and product availability.
Potential benefits include:
– Improving endurance and physical function in some patients.
– Reducing liver and spleen enlargement.
– Improving certain respiratory symptoms.
– Reducing urinary GAG levels.
– Supporting quality of life and everyday functioning.
However, enzyme replacement therapy has important limitations. Many intravenously administered enzymes do not cross the blood–brain barrier in sufficient amounts to treat neurological disease effectively. Therefore, conventional ERT generally does not prevent or reverse the progressive neurological involvement associated with severe MPS I or MPS II.
ERT also does not correct the underlying genetic variant, and ongoing treatment is usually required.

2. Haematopoietic stem cell transplantation (HSCT)
Haematopoietic stem cell transplantation may be recommended for selected children with severe MPS I, particularly before significant neurological damage has occurred.
The transplanted donor cells can produce the enzyme that the patient lacks. This may help improve outcomes, including preserving cognitive function in appropriately selected patients.
However, transplantation carries significant risks, including serious infections, graft-versus-host disease, and treatment-related complications. It is not suitable for every patient and requires evaluation at an experienced specialist centre.
HSCT does not completely prevent all complications, particularly established skeletal abnormalities.

3. Supportive and multidisciplinary treatment
Supportive care is essential for people living with mucopolysaccharidosis, regardless of whether disease-specific treatment is available.
Management may involve:
– Cardiologists for heart valve and cardiac complications.
– Respiratory specialists for airway obstruction and breathing problems.
– Orthopaedic specialists for skeletal abnormalities.
– Physiotherapists for mobility and joint function.
– Audiologists and ophthalmologists for hearing and vision problems.
– Developmental and neurological specialists when needed.
Regular monitoring helps identify complications and guide treatment.

[Genetic Counselor]

Mucopolysaccharidosis (MPS) can develop symptoms at different ages, depending on the specific type of disorder, the severity of the enzyme deficiency, and the rate at which glycosaminoglycans accumulate in the body.

Most children with mucopolysaccharidosis appear normal at birth. Symptoms develop gradually as the accumulated substances begin to affect organs, bones, joints, and other tissues. However, the age of onset and the rate of disease progression vary considerably between individuals.

1. Infancy: Birth to 2 years
In severe forms of mucopolysaccharidosis, the first symptoms may become noticeable during the first year or two of life.
Early features may include:
– Umbilical or inguinal hernias.
– Frequent ear and respiratory infections.
– Persistent nasal congestion and noisy breathing.
– Enlarged liver or spleen.
– Joint stiffness and skeletal abnormalities.
– Delayed achievement of developmental milestones.
For example, children with severe MPS I may develop symptoms during infancy, with progressive involvement of multiple organs. Early recognition is important because some treatment options are more beneficial when initiated before significant complications develop.

2. Early childhood: 2–6 years
Some types of mucopolysaccharidosis become more apparent during early childhood. Parents may notice changes in growth, physical appearance, mobility, or developmental progress.
Children may develop:
– Short stature or abnormal bone growth.
– Increasing joint stiffness.
– Delayed speech and language development.
– Hearing or vision difficulties.
– Recurrent respiratory problems.
– Changes in behaviour or learning abilities.
In MPS III, also known as Sanfilippo syndrome, early symptoms may initially resemble developmental or behavioural disorders. Speech delay, hyperactivity, sleep disturbances, and difficulties with learning may appear before the diagnosis is recognised.

3. Later childhood and adolescence
Milder forms of mucopolysaccharidosis may not be diagnosed until later childhood or adolescence.
In these individuals, symptoms may progress slowly. Skeletal abnormalities, joint pain, short stature, spinal problems, or reduced mobility may be the main reasons for seeking medical attention.
For example, MPS IV, or Morquio syndrome, may become apparent through disproportionate growth, skeletal abnormalities, and joint problems. Intelligence is generally preserved in Morquio syndrome.
Some individuals with attenuated forms of MPS may not receive a diagnosis until adulthood, particularly when their symptoms are relatively mild.

Why does the age of onset vary?
The age at which mucopolysaccharidosis symptoms appear depends partly on the amount of residual enzyme activity. In general, severe enzyme deficiencies are associated with earlier and more rapidly progressive disease, whereas some residual enzyme activity may be associated with a milder course.
However, the relationship is not identical for every MPS type, and symptoms cannot reliably predict the exact genetic variant.

When should MPS be suspected?
A child with unexplained skeletal abnormalities, developmental delays, recurrent infections, hernias, or multiple affected organ systems may require further evaluation.
If mucopolysaccharidosis is suspected, a clinical assessment followed by appropriate biochemical and molecular genetic testing can help establish the diagnosis.

[Genetic Counselor]

Mucopolysaccharidosis (MPS) is a group of rare inherited metabolic disorders caused by deficiencies in specific enzymes required to break down substances called glycosaminoglycans (GAGs). When these substances are not broken down properly, they accumulate in cells and tissues, gradually affecting different organs and body systems.
There is no single first sign of mucopolysaccharidosis (MPS). The earliest symptoms vary depending on the type of MPS, the severity of the enzyme deficiency, and the age at which the disease begins to affect the body.

Common early signs of mucopolysaccharidosis
Some children with MPS develop symptoms during infancy, although they may appear healthy at birth.
– Hernias: Umbilical or inguinal hernias may be among the earliest noticeable signs.
– Frequent ear infections: Recurrent ear infections and hearing difficulties can occur.
– Persistent nasal congestion: A constantly blocked nose, recurrent respiratory infections, or noisy breathing may develop.
– Developmental delays: Some children may take longer to achieve milestones such as walking, speaking, or learning new skills.
– Joint stiffness: Restricted movement, particularly in the fingers and other joints, may become noticeable.
– Enlarged liver or spleen: Accumulation of GAGs can cause enlargement of internal organs.
– Changes in facial features: Some children gradually develop characteristic facial features, including a broad nose, fuller lips, or a prominent forehead.
– Skeletal abnormalities: Short stature, changes in bone development, and spinal abnormalities may develop over time.

Not every child experiences all these symptoms. Some features may also occur in other medical conditions, so their presence alone does not establish a diagnosis.

Are the first signs different in different types of MPS?
Yes. Different types of mucopolysaccharidosis can present differently.
For example, children with MPS I may develop hernias, recurrent respiratory infections, joint stiffness, and skeletal abnormalities. In MPS II, which is also known as Hunter syndrome, symptoms can include enlarged organs, joint problems, and developmental difficulties in some affected individuals.
In MPS III, also called Sanfilippo syndrome, early signs may be more subtle. Speech delay, behavioural changes, hyperactivity, difficulty sleeping, and developmental regression can be early clues. Physical features may be less obvious than in some other MPS types.
In MPS IV, or Morquio syndrome, skeletal abnormalities, short stature, and joint problems may be prominent, while intelligence is generally preserved.

When should parents seek medical advice?
Parents should consult a paediatrician if their child has unexplained developmental delays, multiple hernias, recurrent respiratory or ear infections, unusual skeletal features, or a combination of these symptoms.
When mucopolysaccharidosis is suspected, the doctor may recommend urinary GAG analysis, specific enzyme activity testing, and molecular genetic testing.

[Genetic Counselor]

No single genetic test can find every cause of intellectual disability. Each test is designed to see certain types of DNA changes and misses others. The right test depends on your child’s features, history and family background.

The main tests for intellectual disability,
Karyotype. This looks at whole chromosomes under a microscope. It finds conditions such as Down syndrome but misses small deletions and single-gene changes.

Chromosomal microarray. This finds small missing or extra pieces of chromosomes. It cannot see changes inside a single gene.

Exome sequencing. This reads the protein-coding parts of about 20,000 genes. It finds many single-gene causes of intellectual disability. It usually cannot detect fragile X syndrome, some deletions or imprinting conditions.

Trio exome sequencing. This tests the child and both parents together. It makes it easier to tell whether a change is new in the child or inherited.

Genome sequencing. This reads almost all of the DNA, including many regions outside genes. Some repeat and imprinting conditions still need separate tests.

Fragile X test. This measures one specific repeated stretch of DNA in the FMR1 gene. Fragile X syndrome is the most common inherited cause of intellectual disability.

Metabolic tests. These look for chemical signs of metabolic conditions in blood or urine. Some of these conditions are treatable causes of intellectual disability.

Why exome sequencing cannot see fragile X

Fragile X syndrome is caused by a short stretch of DNA that repeats too many times. Exome sequencing reads DNA in small pieces, so it cannot accurately measure a long repeat. A child with intellectual disability and features of fragile X therefore needs the dedicated fragile X test, even after a normal exome result.

What the guidelines say

In 2021, the American College of Medical Genetics and Genomics recommended exome or genome sequencing as a first- or second-tier test for children with developmental delay or intellectual disability. In 2025, the American Academy of Pediatrics recommended exome or genome sequencing as a first-tier test for most children with unexplained intellectual disability. Across studies, exome or genome sequencing finds a cause in about 28% to 43% of children with intellectual disability. Chromosomal microarray alone finds a cause in about 15% to 20%.

How Genetidoc chooses a test

Team Genetidoc chooses the test after a detailed history and examination, not before:

When the features clearly point to one condition, a targeted test is chosen. Examples are a fragile X test, or methylation testing for Angelman syndrome.
When several causes of intellectual disability are possible, exome sequencing is usually chosen, often together with chromosomal microarray.
Genome sequencing is kept as an escalation step, when a genetic cause is strongly suspected but earlier tests have not found the answer.

[Genetic Counselor]

Often, yes, but not always. Genetic factors are the single largest known cause of intellectual disability. Other causes include:

Infections during pregnancy
A serious lack of oxygen around the time of birth
Extreme prematurity
Brain infections such as meningitis
Untreated low thyroid hormone
Severe malnutrition in early childhood

An Indian study from a tertiary hospital in Delhi shows the balance. Doctors found a cause in more than 8 out of 10 children. Genetic causes were the largest group, explaining about 61% of cases. Problems around the time of birth explained about 20%.

The main genetic causes

Chromosome conditions. Chromosomes are the packages that hold our genes. Down syndrome, caused by an extra copy of chromosome 21, is the most common genetic cause of intellectual disability. Most cases are not inherited from a parent.

Small missing or extra pieces of chromosomes. These are too small to see under a standard microscope. Doctors call them copy number variants. Examples include 22q11.2 deletion syndrome and Williams syndrome.

Changes in a single gene. Scientists have linked well over a thousand genes to intellectual disability, and a change in just one can affect how the brain develops. Some changes appear for the first time in the child. Others are inherited from parents who are healthy carriers.

Fragile X syndrome. This is the most common inherited cause. It involves the FMR1 gene and affects about 1 in 4,000 boys, and fewer girls.

Inherited metabolic conditions. These affect the body’s chemical processes. Some are treatable, such as biotinidase deficiency, which is treated with the vitamin biotin, and phenylketonuria, which is managed with a special diet.

Imprinting conditions. In a few genes, it matters whether the copy came from the mother or the father. Angelman syndrome and Prader-Willi syndrome are examples.

“Genetic” does not always mean “it runs in the family”

Many families assume a genetic condition must have come from someone in the family. In fact, many genetic causes of intellectual disability are new changes that happened for the first time in the child, very early in development. Doctors call these de novo changes. The parents do not carry them, and nothing the parents did during pregnancy caused them.

When doctors suspect a genetic cause

A genetic cause becomes more likely when intellectual disability comes with:

A family history of developmental delay, autism or epilepsy
Parents who are related by blood
Seizures
Birth defects
An unusually small or large head
Facial features that differ from the rest of the family
Loss of skills the child once had

Loss of skills needs prompt medical attention, because some metabolic causes are treatable.

Even when a child’s history includes a difficult birth, a genetic cause is still worth considering. This applies especially when the child’s development does not match what the birth history would suggest. A clinical geneticist can assess the whole picture and decide whether genetic testing is likely to help.

[Genetic Counselor]

The answer depends entirely on the cause. This is one of the most important reasons to find the exact genetic cause before planning another pregnancy.

Chance of it happening again, by type of cause

New (de novo) change. When the change appeared for the first time in the child and neither parent carries it, the chance of it happening again is usually low, around 1%. It is not zero. Rarely, a parent carries the change in some of their egg or sperm cells but not in their blood.

Recessive condition. When both parents are healthy carriers of a change in the same gene, each pregnancy has a 1 in 4 (25%) chance of being affected. This pattern is more common when parents are related by blood, as in cousin marriages seen in some Indian communities.

X-linked condition, with the mother as a carrier. Each son has a 1 in 2 (50%) chance of being affected. Each daughter has a 1 in 2 chance of being a carrier.

Fragile X syndrome. The risk depends on the size of the mother’s repeat in the FMR1 gene. A mother may carry a “premutation”, a medium-sized repeat, without knowing it. Her sisters and other female relatives on her side may benefit from testing too.

Chromosome condition. Conditions such as Down syndrome are usually not inherited. If a parent carries a rearranged chromosome, called a balanced translocation, the risk is higher.
Cause not found. The risk is higher than in the general population but difficult to estimate. Your genetic counselor will discuss it based on your family history.

Options once the exact cause is known

Preimplantation genetic testing with in vitro fertilisation. Embryos are tested before transfer to the womb, and only unaffected embryos are transferred.

Prenatal diagnosis during pregnancy. The baby’s DNA is tested through chorionic villus sampling or amniocentesis. Genetidoc arranges these through partner centres, because it does not currently perform invasive prenatal procedures.

Natural conception without testing, with full information about the risk.

Every family’s decision is personal. The role of genetic counseling is to inform, not to direct.

What a routine pregnancy blood test cannot do

Non-Invasive Prenatal Testing screens the baby’s chromosomes using a blood sample from the mother. It cannot test for most single-gene causes of intellectual disability, and it does not look for the specific change found in your family.

When the affected child has passed away

Some families reach us only after losing a child. If a stored blood or tissue sample is available, it may still be tested. If not, the parents can sometimes be tested to see whether they are carriers, especially when they are related by blood.

Plan before the next pregnancy

Genetic testing and analysis can take weeks to months. Decisions are easier without the pressure of an ongoing pregnancy. If you are thinking about having another child, the best time to speak with a clinical geneticist is before you conceive.

[Genetic Counselor]

This is one of the most common questions parents ask. Most genetic causes of intellectual disability cannot be cured. Even so, a diagnosis can change a child’s care, the family’s future planning and the parents’ peace of mind.

What a diagnosis can change

Treatment for treatable causes. Some causes respond to specific treatment. A 2021 review identified 116 treatable metabolic conditions that can cause intellectual disability. In a Canadian programme that screened 400 children with intellectual disability, about 5% had a treatable condition, and treatment improved behaviour and learning in many of them. Treatment works best when started early. It can prevent further damage but usually cannot undo damage that has already happened.
Better seizure care. Some genetic epilepsies respond well to certain medicines and worse to others. In Dravet syndrome, caused by changes in the SCN1A gene, some common seizure medicines can make seizures worse.
Screening for hidden health problems. Children with Down syndrome need regular thyroid and heart checks. Children with Williams syndrome need heart and calcium monitoring. Children with 22q11.2 deletion syndrome need calcium and immune checks.
An end to the search. A clear answer can stop years of repeated tests, brain scans and hospital visits.
Realistic expectations. Knowing the condition helps doctors explain what the future may look like and which support will help most.
Focused therapy and school planning. Speech, occupational and behavioural therapy can be shaped to the specific condition.
Family planning. The exact cause tells parents and relatives their true chance of having another affected child, and which options are available.
Connection with others. Families can connect with other families living with the same condition and, where available, with research studies.
Clear documentation. A confirmed diagnosis can support applications for disability certification and school support in India. Intellectual disability is a specified disability under the Rights of Persons with Disabilities Act, 2016.

The emotional value of an answer

Many parents carry guilt for years, wondering whether something they did caused their child’s intellectual disability. Relatives may look for someone to blame, often the mother. A genetic diagnosis frequently shows that the change happened by chance, or came from a combination no one could have known about.

A diagnosis does not change who your child is. It changes how well the care team can look after your child, what they watch for, and what they can tell you about a future pregnancy.

An honest note on limitations

Testing does not find an answer for every child. The chance is lower in children with mild learning difficulty and no other features. In one study, only about 6% to 11% of such children received a genetic diagnosis. The chance is higher in children who also have seizures, birth defects, autism, an unusual head size, or parents related by blood.

The decision to test belongs to the family. A genetic counselor can help weigh the likely benefit, the cost, your emotional readiness and your plans for future children. For many families, the value lies not in the report itself but in the decisions it helps them make.

[Genetic Counselor]

Before choosing any screening test in a twin pregnancy, your doctor needs to answer two questions. Are the twins identical or non-identical? And do they share one placenta, or does each baby have its own? The answers shape almost every screening decision that follows.

Identical and non-identical twins

Identical twins come from one fertilized egg that splits into two. They share the same DNA. If one baby has a chromosome condition such as Down syndrome, the other baby almost always has it too.
Non-identical twins come from two separate eggs fertilized by two separate sperm. Genetically, they are like any two brothers or sisters. One baby can have a chromosome condition while the other does not.

One placenta or two

Doctors use the word “chorionicity” to describe how many placentas the twins have.

Twins sharing one placenta (monochorionic twins) are almost always identical.
Twins with two placentas (dichorionic twins) are usually non-identical, but not always. About one in three identical twin pairs also have two separate placentas. This happens when the embryo splits very early, in the first few days after fertilization. So “two placentas” does not prove your twins are non-identical.

How doctors find out

The number of placentas is best seen on an ultrasound scan in the first trimester, ideally before 14 weeks. After that, it becomes much harder to tell. This makes the early scan one of the most important scans of a twin pregnancy. Ask your doctor to note the number of placentas clearly in your scan report.

Why it changes screening

How results are read: With twins sharing a placenta, a chromosome result usually applies to both babies. With non-identical twins, the result may apply to one baby, both, or neither, and a blood test cannot tell which.
The double marker test: This blood test measures two substances made by the placenta. In twins, both placentas release these substances into the same bloodstream, so a healthy baby’s values can mask an affected baby’s values. The number of placentas also affects these measurements, so the risk must be calculated with software adjusted for twins.
Nuchal translucency: This measurement of fluid at the back of each baby’s neck, taken between 11 weeks and 13 weeks 6 days, gives information about each baby separately. In twins, it carries more weight than the blood markers.
Diagnostic testing: If a result is concerning, twins with two placentas usually need each baby tested separately. For twins sharing a placenta, one sample is often enough when both babies look alike on scan.

Extra monitoring for twins sharing a placenta

Twins sharing a placenta need frequent scans, often every two weeks from around 16 weeks. These look for complications such as twin-to-twin transfusion syndrome, where blood flow between the babies becomes unbalanced. In these twins, a large difference in neck fluid or size between the two babies can also be an early sign of placental complications, not only of a genetic condition.

[Author]

Posts